Sugi Predict

Sugi Predict / Targets / MTAP

MTAP

S-methyl-5'-thioadenosine phosphorylase · Q13126 · MTAP on Sugi Atlas →

1,502 patent compounds predicted against MTAP, 933 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1221607 SCHEMBL1221607 1.00 20/20
SCHEMBL1222149 SCHEMBL1222149 1.00 20/20
SCHEMBL1223121 SCHEMBL1223121 1.00 20/20
SCHEMBL1223230 SCHEMBL1223230 1.00 20/20
SCHEMBL14444462 SCHEMBL14444462 0.74 20/20
SCHEMBL1221977 SCHEMBL1221977 0.72 20/20
SCHEMBL1222123 SCHEMBL1222123 0.72 20/20
SCHEMBL1222700 SCHEMBL1222700 0.72 20/20
SCHEMBL1222904 SCHEMBL1222904 0.72 20/20
SCHEMBL1223550 SCHEMBL1223550 0.72 20/20
SCHEMBL1221792 SCHEMBL1221792 0.72 20/20
SCHEMBL1221841 SCHEMBL1221841 0.72 20/20
SCHEMBL1222823 SCHEMBL1222823 0.72 20/20
SCHEMBL14262851 SCHEMBL14262851 0.72 20/20
SCHEMBL1222989 SCHEMBL1222989 0.61 20/20
SCHEMBL1222991 SCHEMBL1222991 0.61 20/20
SCHEMBL1222996 SCHEMBL1222996 0.61 20/20
SCHEMBL1222220 SCHEMBL1222220 0.61 20/20
SCHEMBL1222658 SCHEMBL1222658 0.61 20/20
SCHEMBL1222951 SCHEMBL1222951 0.61 20/20

Clinical trials — most relevant to MTAP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Alanosine in Treating Patients With Cancer PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors PHASE1/PHASE2RECRUITING
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer PHASE2COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung PHASE2COMPLETED
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers PHASE2WITHDRAWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome PHASE2COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients PHASE1/PHASE2COMPLETED
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors PHASE1RECRUITING
Study of GS-5319 in Adults With Solid Tumors PHASE1RECRUITING
Study of GS-2426 in Participants With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma PHASE1COMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia nanCOMPLETED
Effect of DNMT SNPs on DNA Methylation in Primary ITP nanUNKNOWN
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia nanCOMPLETED
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study nanNOT_YET_RECRUITING
Using the Epitranscriptome to Diagnose and Treat Gliomas nanRECRUITING
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart nanUNKNOWN
Prognosis of METTL-14 in Endometrial Carcinoma nanNOT_YET_RECRUITING
The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MTAP binder may also engage these)

ProteinNameSimilarity
F6RQL9 — 1.000 F6RQL9 →
Q3MHF7 — 0.984 Q3MHF7 →
Q9CQ65 — 0.979 Q9CQ65 →
Q91ZH7 — 0.935 Q91ZH7 →
GABBR1 Gamma-aminobutyric acid type B receptor subunit 1 0.934 landscape →
Q13888 — 0.934 Q13888 →
Q0VC00 — 0.931 Q0VC00 →
Q9WV18 — 0.931 Q9WV18 →
Q9Z0U4 — 0.931 Q9Z0U4 →
Q5R797 — 0.929 Q5R797 →
Q5ZJQ7 — 0.929 Q5ZJQ7 →
Q6P1K8 — 0.928 Q6P1K8 →
P41091 — 0.928 P41091 →
Q2KHU8 — 0.928 Q2KHU8 →
F1QGW6 — 0.927 F1QGW6 →
Q6NVL5 — 0.927 Q6NVL5 →
P81795 — 0.926 P81795 →
Q2TBV5 — 0.926 Q2TBV5 →
Q5ZMS3 — 0.926 Q5ZMS3 →
F1LTR1 — 0.925 F1LTR1 →
Q9Z0N1 — 0.925 Q9Z0N1 →
SSU72 RNA polymerase II subunit A C-terminal domain phosphatase SSU72 0.925 landscape →
Q5SP67 — 0.924 Q5SP67 →
Q4KLK9 — 0.923 Q4KLK9 →
P20461 — 0.923 P20461 →
Q2VIR3 — 0.922 Q2VIR3 →
Q5ZHS1 — 0.922 Q5ZHS1 →
P63073 — 0.922 P63073 →
Q9NQX3 — 0.922 Q9NQX3 →
Q17QI2 — 0.921 Q17QI2 →